Edition:
United States

Regenxbio Inc (RGNX.OQ)

RGNX.OQ on NASDAQ Stock Exchange Global Select Market

28.75USD
11:26am EST
Change (% chg)

$0.95 (+3.42%)
Prev Close
$27.80
Open
$27.90
Day's High
$29.35
Day's Low
$27.90
Volume
25,501
Avg. Vol
83,814
52-wk High
$35.95
52-wk Low
$16.30

Chart for

About

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates... (more)

Overall

Beta: --
Market Cap(Mil.): $865.84
Shares Outstanding(Mil.): 31.15
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 200.64 15.49
EPS (TTM): -- -- --
ROI: -- -10.01 11.95
ROE: -- -35.77 15.94

BRIEF-Regenxbio reports third quarter financial results

* Regenxbio reports third quarter 2017 financial results and recent operational highlights

Nov 08 2017

BRIEF-RTW Investments reports 5 pct passive stake in Regenxbio

* RTW Investments reports a 5 percent passive stake in Regenxbio Inc as of October 2, 2017 - SEC filing Source text for Eikon: (http://bit.ly/2xkVMYD) Further company coverage:

Oct 05 2017

BRIEF-Dimension Therapeutics says on termination of merger with Ultragenyx co will be required to pay Ultragenyx a termination fee of $2.9 mln-SEC filing

* Dimension Therapeutics says on termination of merger with Ultragenyx co will be required to pay Ultragenyx a termination fee of $2.9 million-SEC filing

Oct 03 2017

BRIEF-Regenxbio announces completion of dosing of first cohort in Phase I clinical trial of RGX-314 gene therapy for wet AMD

* Regenxbio announces completion of dosing of first cohort in Phase I clinical trial of RGX-314 gene therapy for wet AMD

Sep 20 2017

BRIEF-Dimension Therapeutics says co's board determined proposal from Ultragenyx Pharmaceutical could reasonably be expected to lead to "superior proposal"​

* Dimension Therapeutics - ‍Dimension board determines proposal from Ultragenyx Pharmaceutical could reasonably be expected to lead to "superior proposal"​

Sep 19 2017

BRIEF-Regenxbio to acquire Dimension Therapeutics

* Dimension Therapeutics Inc says ‍boards of directors of both companies have unanimously approved transaction​

Aug 25 2017

Earnings vs. Estimates